NRIX Nurix Therapeutics Inc

$NRIX Nurix printed a profit, which is not really the business yet. Fiscal Q3 revenue was 673.1 million dollars, but 653.2 million of it was one license recognition from the Roche collaboration. Collaboration revenue itself was 19.9 million, a bit below the 21.5 million analysts expected (MT Newswires). Diluted EPS was 4.73 vs a 1.03 loss a year ago, and cash is now 1.1 billion dollars, runway into the second half of 2029 per the company. The Roche money funds the pipeline. It does not change what the recurring revenue looks like.

$NRIX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $4.73 up 559.22% YoY • Reported revenue of $673.06M up 8430.54% YoY • Nurix expects existing cash, cash equivalents and marketable securities of $1.1B to fund operations, including clinical trials and infrastructure, for at least the next 12 months; additional funding will be needed.

$NRIX key highlights from today's Q3 earnings: > $1.1B cash runway through H2 2029 thanks to Roche deal > NX-2127 has been discontinued. I thought this drug had potential but I guess this allows us to focus on bexdeg (and NX-1607) > NX-1607 moved into phase 1b Less than a month till we get to see ASH abstracts. This might be our last chance to buy shares in the low 20s.